Written by: Ellie Pranckevicius, FNP-BC, Aesthetic Nurse Practitioner & Aesthetic Injector | Facial Restoration & Regenerative Injectable Specialist, Mirror Plastic Surgery
Key Takeaways
- Only specific 17β-estradiol and micronized progesterone products qualify as FDA-approved bioidentical hormones after rigorous safety, efficacy, and manufacturing review.
- FDA-approved options come as patches, gels, sprays, oral capsules, and vaginal inserts, with brands such as Vivelle-Dot, Climara, Prometrium®, and Bijuva®.
- Compounded bioidentical hormones lack FDA oversight for potency, purity, and safety labeling, which increases potential risk compared with approved formulations.
- Breast cancer and cardiovascular risks depend on formulation, dose, and delivery route. The lowest absolute risks appear with low-dose transdermal estrogen plus micronized progesterone started before age 60 or within 10 years of menopause.1
- Schedule a personalized consultation at Mirror Plastic Surgery in St. Petersburg to review your labs and decide whether an FDA-approved bioidentical hormone regimen fits your needs.
FDA-Approved Bioidentical Hormones Available Today
Two active ingredients form the foundation of every FDA-approved bioidentical hormone product currently available in the United States.
- 17β-estradiol, the primary estrogen produced by the ovaries, appears in multiple delivery forms across numerous brand names and carries full FDA regulatory status for menopausal symptom relief and osteoporosis risk reduction.
- Micronized progesterone, a progesterone molecule processed to match the body’s own hormone, is available under the brand name Prometrium® and is indicated for endometrial protection in women with a uterus who use systemic estrogen.
The FDA organizes approved hormone medicines for menopause into four categories: Estrogen-Only Medicines, Progestin-Only Medicines, Combination Estrogen and Progestin Medicines, and Combination Estrogen and Other Medicines. No additional bioidentical hormone therapies for hormone replacement have been added to this approved list.
Delivery Methods and Brand Examples in 2026
The table below shows how the two FDA-approved bioidentical hormones appear across common brand-name products, highlighting that the same active ingredient can be delivered through several routes based on symptoms and personal preference.
| Hormone | Representative Brand Names | Delivery Method |
|---|---|---|
| 17β-estradiol (systemic) | Vivelle-Dot, Climara, Estrogel, Evamist, Femring | Patches, gels, sprays, vaginal rings, oral tablets, and injections |
| 17β-estradiol (systemic, oral) | Estrace | Pill |
| 17β-estradiol (vaginal/topical) | Vagifem, Imvexxy, Estring | Vaginal tablet, insert, cream, ring |
| Micronized progesterone | Prometrium® | Oral capsule, sometimes administered vaginally |
| Estradiol + micronized progesterone (combination) | Bijuva® | Single oral capsule (1 mg/100 mg) |
Is estradiol bioidentical? Yes. 17β-estradiol is molecularly identical to the estrogen produced by the human body, which distinguishes it from older synthetic alternatives such as conjugated equine estrogens. All FDA-approved estradiol products, whether delivered transdermally, orally, or vaginally, meet this definition.
Are injectables bioidentical? Standard FDA-approved hormone therapy for menopause is not typically administered by injection, and most women use estrogen patches, gels, or oral pills. Injectable estradiol formulations exist but are not primary FDA-approved delivery methods for menopausal hormone therapy, which often creates confusion about routes of administration.
Compounded vs. FDA-Approved Bioidentical Hormones
Compounded bioidentical hormones made by compounding pharmacies are not regulated by the FDA for safety and efficacy as menopause treatment, while FDA-approved products undergo detailed review for potency, purity, and manufacturing consistency.
Key regulatory distinctions include the following points.
- Compounded preparations are not subject to enforced good manufacturing standards, quality controls, or post-market monitoring.
- Compounded hormone products may contain undesirable additives, preservatives, degradation products, residual solvents, or bacterial endotoxins.
- Inconsistencies in estradiol quantities in compounded preparations can increase the risk of venous thromboembolism and endometrial cancer.
- Compounded preparations do not carry the safety warnings required on all FDA-approved estrogen products.
- Experts from the National Academy of Medicine advise against the use of compounded bioidentical hormones except for specific medical circumstances.
- ACOG’s 2023 Clinical Consensus states that compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations are available.
Safety, Cancer Risk, and Timing of Therapy
Cancer risk associated with hormone therapy is real, depends on formulation, and is easiest to understand in absolute rather than relative terms.
Large cohort studies show an increase in breast cancer risk with HRT use, and the risk varies by formulation such as estrogen-only or combined estrogen-progestogen. Recent studies indicate that the breast cancer risk increase with modern bioidentical hormone therapy may be smaller than previously thought.1 However, timing remains critical.
A 2026 retrospective cohort study of 83,147 women found that initiating or continuing menopausal hormone therapy after age 65 was associated with higher risks of cancer and vascular events.1 These findings support careful age-based assessment before starting or extending therapy.
Cardiovascular and clotting risk also vary significantly by delivery route. The absolute risk of venous thromboembolism and stroke is very small when treatment begins before age 60 or within 10 years of menopause using low-dose transdermal estrogen combined with micronized progesterone in otherwise healthy women.1 Transdermal estrogen does not pass through the liver and therefore has less impact on clotting factors compared with oral formulations.
In November 2025, the FDA announced the initiation of removal of the black box warning labels from menopausal hormone therapy products, reversing a 2002 decision based on the Women’s Health Initiative study. The same month, the agency extended this policy shift to low-dose vaginal estrogen therapies.
Talking with Your Doctor About Hormone Options
Preparing specific questions before a provider visit leads to more productive conversations about hormone therapy. The following questions focus on formulation choice, baseline assessment, and ongoing monitoring, which shape whether a regimen stays both safe and effective for you.
- Which FDA-approved estradiol or progesterone formulation fits my symptom profile and health history?
- What baseline labs, such as estradiol, FSH, LH, and thyroid function, should be drawn before starting?
- Does my uterine status affect which combination of hormones I need?
- What delivery route minimizes my individual cardiovascular or clotting risk?
- How will we monitor my response and reassess risk-benefit over time?
What to Expect When You Stop Therapy
Women can try hormone therapy for a short three-month period to see whether menopausal symptoms decrease, and they can stop and restart to confirm effectiveness, provided there are no medical contraindications. When therapy stops, menopausal symptoms usually return gradually. Hormone therapy reduces fracture risk by 30–40% by preventing rapid bone loss in early menopause.1 so decisions about discontinuation should include bone density status. Many clinicians use tapering rather than abrupt cessation to reduce symptom rebound, although the ideal tapering schedule remains individualized.
Key Concepts and Hormone Terminology
- Bioidentical: A hormone whose molecular structure is identical to the hormone naturally produced by the human body, not a regulatory or safety classification on its own.
- FDA-approved: A product that has completed the FDA’s review process for safety, efficacy, manufacturing quality, and labeling, and that remains under ongoing post-market surveillance.
- Compounded: A preparation custom-made by a compounding pharmacy, typically not subject to FDA pre-market approval, standardized manufacturing requirements, or mandatory safety labeling.
Important Individual Factors to Weigh
Bioidentical hormones are not automatically safer than other hormone formulations, and safety depends on the type of hormone, delivery route, dose, patient health history, and monitoring. One key safety consideration is uterine status. Women with an intact uterus require both estrogen and progesterone to protect against endometrial hyperplasia, while women who have had a hysterectomy may use estrogen alone.
The Menopause Society recommends a personalized approach to hormone therapy with regular reassessment of risks and benefits as women age. Lab monitoring at initiation and at regular intervals is standard practice for all hormone regimens.
Risks, Limitations, and Real-World Challenges
NAMS, ACOG, and NICE guidelines recommend individualized menopausal hormone therapy at the lowest effective dose, continued for as long as benefits outweigh risks, with no arbitrary age-based cutoff for stopping. Challenges include individual variability in symptom response, the need for ongoing lab monitoring, and the complexity of weighing breast cancer, cardiovascular, and bone health data at the same time. The US Preventive Services Task Force recommends against using hormone therapy solely for primary prevention of chronic conditions such as heart disease in postmenopausal persons.
Common Misconceptions About Bioidentical Hormones
- “All bioidentical hormones are FDA-approved.” Incorrect. Compounded bioidentical hormones from compounding pharmacies are not regulated by the FDA for safety and efficacy, and only specific manufactured products with FDA approval meet that standard.
- “Compounded hormones are more natural and therefore safer.” Compounded preparations may contain undesirable additives, inconsistent hormone quantities, and lack the safety warnings required on FDA-approved products.
- “Saliva testing accurately guides compounded hormone dosing.” Saliva and serum testing used to determine precise hormone requirements for compounded therapy lacks substantiation through rigorous research and is not recommended by menopause societies.
- “The five-year rule still applies.” This guideline has been retired, and duration is now individualized by ACOG and the Menopause Society based on ongoing risk-benefit assessment.
Practitioner Perspective: How Ellie Approaches Hormone Care
Ellie Pranckevicius, FNP-BC, leads hormone-related wellness consultations at Mirror Plastic Surgery in St. Petersburg, Florida. Her clinical foundation includes four years in the Neuroscience ICU at Tampa General Hospital, where she developed deep expertise in physiology, metabolic health, and the body’s recovery capacity. Ellie’s approach to hormone and wellness consultations centers on in-depth lab interpretation, reviewing estradiol, FSH, LH, thyroid, and metabolic markers before building any individualized protocol. Her dual background in esthetic care and advanced nursing allows her to address both the clinical and quality-of-life dimensions of hormone-related concerns within a concierge care model that prioritizes education and long-term outcomes over volume.
Book an appointment with Ellie to discuss your hormone health with a clinician who interprets labs in the context of your full symptom picture.
Frequently Asked Questions
Which bioidentical hormones are FDA approved?
The two active ingredients with FDA-approved bioidentical status are 17β-estradiol and micronized progesterone. Estradiol is available in patches, gels, sprays, vaginal rings, vaginal tablets, vaginal inserts, and oral pills. Micronized progesterone is available as an oral capsule under the brand name Prometrium®, and in combination with estradiol in the single-capsule product Bijuva®.
Is estradiol bioidentical?
Yes. 17β-estradiol is molecularly identical to the primary estrogen produced by the human ovaries, which defines a bioidentical hormone. All FDA-approved estradiol products, regardless of delivery method, share this molecular identity. This feature distinguishes them from conjugated equine estrogens, which are derived from horse urine and contain a mixture of estrogen compounds not identical to human estradiol.
What is the cancer risk associated with FDA-approved bioidentical hormones?
Breast cancer risk varies by formulation, route, and duration. Estrogen-only therapy carries a lower breast cancer risk than combined estrogen-progestogen therapy. Large cohort studies show an increase in breast cancer risk with use of HRT, although recent research suggests the increase with modern bioidentical hormone therapy may be smaller than previously thought. As noted in the safety section, transdermal estrogen combined with micronized progesterone carries lower venous thromboembolism and stroke risk than oral formulations, especially when started within the optimal timing window. The 2026 cohort study mentioned earlier found elevated cancer and vascular risks when therapy was initiated or continued after age 65.
How do FDA-approved bioidentical hormones differ from compounded preparations?
FDA-approved products undergo pre-market review for safety, efficacy, potency, purity, and manufacturing consistency, and they carry required safety labeling. Compounded preparations are custom-made by pharmacies and are not subject to FDA pre-market approval, standardized manufacturing requirements, or mandatory safety warnings. ACOG, the Menopause Society, and the National Academy of Medicine advise against routine use of compounded bioidentical hormones when FDA-approved alternatives are available. Clinicians generally reserve compounded formulations for situations where a standard product does not exist at the required dose or delivery form for a specific patient.
How long can someone stay on FDA-approved bioidentical hormone therapy?
There is no fixed maximum duration. As discussed earlier, the five-year rule has been retired in favor of individualized assessment. Current guidance recommends using the lowest effective dose for as long as benefits outweigh risks, with no arbitrary age-based cutoff. Duration decisions are tailored based on symptom control, bone density, cardiovascular health, breast cancer risk factors, and patient preference, with regular reassessment at each clinical visit. Women under 60 who are within 10 years of menopause onset generally have the most favorable risk-benefit profile for initiating and continuing therapy.
Hormone therapy decisions involve several variables, including symptom severity, lab values, health history, delivery route, and personal risk tolerance. The information in this guide supports informed conversations with a qualified provider and does not replace individualized clinical evaluation.
Ready to move forward? Schedule your consultation at Mirror Plastic Surgery in St. Petersburg, Florida, to begin a lab-informed, personalized discussion about your hormone health options.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
Peptide therapy is intended for wellness and optimization purposes and is not prescribed to diagnose, treat, cure, or prevent disease unless specifically stated. Many peptides are not FDA-approved and may be used off-label. Some have limited long-term safety data, with a potential for unknown risks, complications, or desensitization with prolonged use.
